ArticleBMC health services research2019

Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines.

Anne Julienne Genuino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.